The role of combination therapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
Gonzalez
Chris M
CM
Department of Urology, Northwestern University Medical School, 303 E. Chicago Ave., Tarry 11-715, Chicago, IL 60611, USA.
McVary
Kevin T
KT
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D018450:Disease Progression; D017292:Doxazosin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D018120:Finasteride / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D016896:Treatment Outcome
D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; C041226:Terazosin; D017292:Doxazosin; D011224:Prazosin